Shionogi Inc. (U.S.)

FDA Approves Ensitrelvir (XOCOVA) as First Oral Option for COVID-19 Post-Exposure Prophylaxis

FDA · COVID-19 · 5 min

The FDA has approved Shionogi's ensitrelvir (XOCOVA) as the first and only oral antiviral for post-exposure prophylaxis of COVID-19. This approval addresses a critical prevention gap and introduces a convenient five-day oral regimen.

FDA Approves First Oral COVID-19 PEP Drug, Xocova

FDA · COVID-19 · 4 min

The FDA has approved Shionogi's Xocova (ensitrelvir) as the first oral post-exposure prophylaxis (PEP) for COVID-19 in adults and adolescents aged 12 years and older. The approval is based on the Phase 3 SCORPIO-PEP trial.

FDA Approves Xocova: A Catalyst for Pharmaceutical M&A and Licensing

FDA · 8 min

The FDA has approved Shionogi's Xocova, marking a significant development in COVID-19 prevention. This approval coincides with a surge in pharmaceutical industry mergers and licensing deals, signaling a dynamic period for the sector.

FDA Approves Ensitrelvir for Post-Exposure Prophylaxis of COVID-19

FDA · COVID-19 · 8 min

Structured plan for FDA Approves Ensitrelvir for Post-Exposure Prophylaxis of COVID-19

Shionogi's Xocova Gains FDA Clearance for COVID-19 Post-Exposure Prevention

FDA · COVID-19 · 7 min

Shionogi's COVID-19 antiviral, Xocova, has secured FDA approval for use as a post-exposure preventative measure. This clearance expands the therapeutic landscape for managing SARS-CoV-2 infections.